New UK Biotech MiroBio Raises $34m For Autoimmune Disease Research
Company is keeping its cards close to chest on exact mechanism as it enters increasingly competitive autoimmune disease field.
You may also be interested in...
VC deals totaled $8.3bn in the first half of 2019, but the year's total rose to just $11.5bn at the end of September, reflecting only a $3.2bn third quarter gain. Among recent financings, Cygnal emerged from stealth mode with $65m invested to date.
Sanofi is playing catch-up in oncology and hopes Synthorx’s expertise will help the group advance.
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.